Immunovia Completes Acquisition of Blood Samples
Immunovia, known for its advancements in pancreatic cancer diagnostics, has successfully acquired all necessary blood samples for the clinical validation of its next-generation pancreatic cancer test. This achievement marks a significant milestone in the company’s ongoing commitment to improving early detection methods for this dangerous disease.
Significance of the Clinical Validation Study
The clinical validation study aims to confirm the sensitivity and specificity of the new test, which had previously been reported during its model-development phase. This pivotal trial will involve a case-control design, specifically assessing the accuracy of the test in distinguishing blood samples from individuals diagnosed with early-stage pancreatic cancer from those without the disease.
Collection of Blood Samples
Immunovia has successfully secured over 1,000 blood samples. This impressive collection includes more than 200 samples from patients diagnosed with stage 1 and stage 2 pancreatic cancer. Additionally, the company has gathered over 800 samples from high-risk individuals who are currently cancer-free, making this study one of the largest for clinical validation of a pancreatic cancer biomarker test conducted to date.
Collaboration and Expert Contributions
The acquisition of blood samples was facilitated through Immunovia’s strong relationships with leading researchers in pancreatic cancer centers located in various regions. Noteworthy collaborators who contributed significantly include Dr. Randall Brand from the University of Pittsburgh, Dr. Rosie Sears from Oregon Health and Science University, and Dr. Salvatore Paiella from the University of Verona. Their collaboration is invaluable in enhancing the breadth and depth of the study sample.
Partnership with the PRECEDE Consortium
This initiative also signifies Immunovia's inaugural research collaboration with the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Led by Dr. Diane Simeone, the PRECEDE Consortium comprises a multi-institutional network of experts focused on advancing early pancreatic cancer detection through innovative collaboration and data sharing. The consortium has contributed nearly 500 samples from its ongoing studies targeting individuals at increased risk for hereditary cancers.
CEO’s Remarks on Study Progress
CEO Jeff Borcherding expressed enthusiasm about reaching this crucial milestone, stating, "We are excited to announce that we have secured all samples required to clinically validate our next-generation test. This study represents a pivotal step in our mission to bring early detection of pancreatic cancer to high-risk individuals." His words reflect the company’s dedication to making breakthroughs in this formidable area.
Looking Ahead: Clinical Validation Completion
As previously mentioned by the company officials, Immunovia expects to conclude the clinical validation study by December 2024. This timeline is aimed at preparing for the launch of the next-generation pancreatic cancer detection test, anticipated for release later in 2025, a development that holds great promise for patients at substantial risk.
About Immunovia
Immunovia AB is dedicated to increasing survival rates among pancreatic cancer patients through early detection solutions. The company focuses on creating straightforward blood tests to identify proteins and antibodies that may indicate an individual is at high risk for developing pancreatic cancer. Through partnerships with healthcare providers, leading specialists, and advocacy groups, Immunovia is determined to enhance accessibility to its tests for those at elevated risk.
Market Insights
With the USA being the largest market for pancreatic cancer detection, Immunovia's efforts are particularly timely. It is estimated that around 1.8 million individuals in the country are at high risk of developing pancreatic cancer and could significantly benefit from annual surveillance testing.
Frequently Asked Questions
What is Immunovia's latest achievement in cancer detection?
Immunovia has acquired all the blood samples necessary for the clinical validation of its next-generation pancreatic cancer test.
How many samples did Immunovia collect for the study?
The company secured over 1,000 blood samples, including more than 200 from stage 1 and 2 pancreatic cancer patients.
What type of study is being conducted by Immunovia?
The study is a case-control trial aimed at evaluating the accuracy of the new test in differentiating early-stage pancreatic cancer cases from high-risk individuals without the disease.
What is the role of the PRECEDE Consortium in the study?
The PRECEDE Consortium provides valuable samples and collaboration to enhance the success of the clinical validation study.
When does Immunovia expect to complete the clinical validation process?
Immunovia anticipates concluding the clinical validation study by December 2024, ahead of launching the test in 2025.
